Last reviewed · How we verify

Ketorolac Injection

Massachusetts General Hospital · FDA-approved active Small molecule Quality 2/100

Ketorolac Injection is a Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved. Also known as: Toradol, Aculare, Allergan.

At a glance

Generic nameKetorolac Injection
Also known asToradol, Aculare, Allergan
SponsorMassachusetts General Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketorolac Injection

What is Ketorolac Injection?

Ketorolac Injection is a Small molecule drug developed by Massachusetts General Hospital.

Who makes Ketorolac Injection?

Ketorolac Injection is developed and marketed by Massachusetts General Hospital (see full Massachusetts General Hospital pipeline at /company/massachusetts-general-hospital).

Is Ketorolac Injection also known as anything else?

Ketorolac Injection is also known as Toradol, Aculare, Allergan.

What development phase is Ketorolac Injection in?

Ketorolac Injection is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing